IPN Ipsen S.A.

178.12USD162.40 EUR · EPA+0.06%Mkt Cap: 14.68B USDP/E: 26.28

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Soma…

Institutional holders12 on file

Key Statistics

Company
Market Cap14.68B USD
Enterprise Value13.58B USD
Revenue (TTM)4.71B USD
Gross Profit3.49B USD
Net Income (TTM)486.43M USD
Revenue/Share57.03 USD
Last Price178.12 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5.5K
CountryFR
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINFR0010259150
Valuation
P/E (Trailing)26.28
P/E (Forward)11.23
PEG0.49
EV/EBITDA8.29
EV/Revenue2.88
P/S3.12
P/B2.84
EPS (TTM)6.78 USD
EPS (Forward)15.86 USD
52W Range
126.7980% of range190.84
52W High190.84 USD
52W Low126.79 USD
Profitability
Gross Margin80.89%
Oper. Margin27.38%
EBITDA Margin34.80%
Profit Margin11.29%
ROE10.23%
ROA6.39%
ROIC19.77%
ROCE17.19%
Growth
Revenue Growth18.70%
Earnings Growth21.50%
Cash Flow & Leverage
Operating CF1.25B USD
CapEx (TTM)360.52M USD
FCF Margin24.09%
FCF Yield7.72%
Net Debt-1.11B USD
Net Debt/EBITDA-0.68
Net Debt/FCF-0.98
Balance Sheet
Debt/Equity0.20
Current Ratio1.97
Quick Ratio1.77
Book Value/Sh62.68 USD
Cash/Share26.23 USD
Dividends
Fwd Div Rate1.75 USD
Trail. Div Rate1.75 USD
Div. Yield0.98%
5Y Avg Yield1.09%
Payout Ratio25.89%
Ex-Div DateJun 3, 2026
Pay Date—
Analyst Consensus
Rating2.8 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)177.93 USD
Upside (mean)-0.1%
Target Range142.58 USD – 257.75 USD
142.58-0.1% to mean257.75
# Analysts13
Ownership
Shares Out.82.43M
Float29.97M
Insiders57.64%
Institutions22.05%
Technical
SMA 50167.26 (+6.5%)
SMA 200173.97 (+2.4%)
Beta0.32
S&P 52W Chg12.00%
Avg Vol (30d)104.92K
Avg Vol (10d)102.09K
Technical Indicators
RSI (14)58.5
MACD3.7006
MACD Signal3.6318
MACD Hist.+0.0688
BB Upper187.67 USD
BB Middle174.96 USD
BB Lower162.26 USD
BB Width14.52%
ATR (14)4.041 USD
Vol Ratio (20d)1.13x

About Ipsen (EPA: IPN)

›

Ipsen (EPA: IPN) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 5,535 employees.

The shares were at 162.40 EUR on 19 November 2026, up 27.8% over 52 weeks. Its 52-week range is 115.60 EUR to 174.00 EUR: the price is 6.7% below the high and 40.5% above the low.

At a market capitalisation of 13.39B EUR, it trades at 26.3 times trailing earnings and 11.2 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, so IPN is valued in line with them. It pays a dividend yielding 0.98% (it pays out 26% of its earnings), against a median of 2.01% among the dividend payers in that peer group.

Ipsen reports return on equity of 10.2%, an operating margin of 27.4% and revenue up 18.7% year over year.

It holds more cash than debt, a net cash position of 1.01B EUR. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 13 analysts cover the stock, with an average rating of Hold; their mean price target of 162.23 EUR is 0.1% below the current price. The next earnings report is expected on 11 February 2027.